Friday, 23 October 2026 Updated 13 min ago
The News Engine
Breaking
Health United Kingdom

‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows

It is the first individualised cancer vaccine to show positive results in a phase III clinical trial.

Image accompanying the story: ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
Image: Photograph: Tim Bauer · via The Guardian

According to The Guardian, it is the first individualised cancer vaccine to show positive results in a phase III clinical trial.

The vaccine, intismeran, is custom-made to target genetic mutations unique to an individual’s melanoma.

This health story centres on the United Kingdom.

Why it matters

Health developments can affect patients, healthcare providers and public-health planning.

Key details

Location
United Kingdom · Europe
Reported by
The Guardian
First reported
Key names
III
Section
Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

Read the full story at The Guardian

Spotted an error? Request a correction · How this summary was produced

Related Stories